���ӽ紫ý

Patients starting SSRIs and lecanemab may warrant close monitoring

UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E

The drugs clear sticky plaques from the brain. But they are not for everyone, experts caution

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug meeting with the Food and Drug Administration related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). The CAB includes six members with diverse backgrounds and expertise in dementia, Alzheimer’s disease, inflammation, neurodegenerative disorders, and drug development.

In the first decade of the last century a young German psychiatrist discovered a new disease. But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis. As a result the “A-word” now has a particularly scary connotation for senior citizens. Perhaps it is because it is normal to experience memory loss as we age.

In the first decade of the last century, a young German psychiatrist discovered a new disease. But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis. As a result, the “A-word” now has a particularly scary connotation for senior citizens. Perhaps it is because it is normal to experience memory loss as we age.

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

It’s called the Chambers-Grundy Center for Transformative Neuroscience at ���ӽ紫ý, and the adjective in the name says it all.

Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.